SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

Immunocompromised individuals are at a 6 to 11 times higher risk of developing herpes zoster compared to the general population, with hematopoietic stem cell transplant recipients facing the highest risk.

Timely diagnosis and intervention are crucial in managing acute abdominal pain, as emergency general surgery is an independent risk factor for postoperative complications and death.

Yellow nail syndrome presents a diagnostic puzzle, with its triad of symptoms potentially occurring asynchronously. Early recognition can lead to appropriate management and improved patient outcomes.

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.

Kisunla’s approval introduces a novel treatment option for early Alzheimer’s disease, potentially altering the landscape of AD management with its ability to significantly reduce amyloid plaque levels and slow cognitive decline.